Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mereo BioPharma Group PLC

MREO ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.29

▼ -4.08%

Market Cap $46.23M · Vol 106.83K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$46.23M

Micro Cap

Div Yield

N/A

EPS Growth

+30.00%

YoY

RSI (14)

35.55

Momentum

Beta

0.19

vs Market

52W High

$2.37

87.78% below

52W Low

$0.20

44.75% above

Volume

106.83K

Avg 136.46K

P/B

1.62

Price-to-book

ROE

-82.21%

Return on equity

Free Float

99.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mereo BioPharma Group PLC (MREO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MREO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.77%

-27.99%

-8.10%

+7.86%

YTD

-30.53%

-84.68%

-85.56%

-87.13%

Financials & Valuation

TTM · Annual

Total Revenue	$500.00K
Net Income	$-41,878,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	73.40%
Operating Margin	-8,021.40%
Net Profit Margin	-8,375.60%
ROE	-82.21%
ROA · ROIC	-68.48% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	132.86
P/B	1.62
P/FCF	N/A
EPS Growth	+30.00%
Outstanding Shares	798.45M

Technical Indicators

50-Day SMA	$0.31
200-Day SMA	$0.33
RSI (14)	35.55
Beta	0.19
52-Week High	$2.37
52-Week Low	$0.20

Volume Today	106.83K
Avg Daily Volume (30D)	136.46K
Relative Volume	0.78x
Volatility (10D)	43.21
Volatility (30D)	80.82
Free Float	99.25%

Analyst Consensus

BUY

Current Price $0.29

Mean Target $1.75

52W Low$0.20 52W High$2.37

Current

Target

$0.20 $2.37

Current Analyst target

+504.49% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00KFWZCX7

ISINUS5894921072

CountryUK

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.